Abstract
Get full access to this article
View all access options for this article.
References
1.
Kummar
S.
,
Kinders
R.
,
Gutierrez
M.
,
Rubinstein
L.
,
Parchment
R.E.
,
Phillips
L.R.
,
Low
J.
,
Murgo
A.J.
,
Tomaszewski
J.E.
,
Doroshow
J.H.
, NCI Phase 0 Working
Group: Inhibition of poly (ADP ribose) polymerase (PARP) by ABT-888 in
patients with advanced malignancies: Results of a phase 0
trial.
J Clin Oncol , 2007 ASCO Annual Meeting Proc, 18S:
abstr 3518, 2007.
2.
Willis
R.C.
: What is phase
zero?
Scientist,
19 : 38 , 2005 .
3.
von Eschenbach
A.C.
: New FDA guidance aims
to speed early drug development.
NCI Cancer Bulletin,
3 (3 ): 1 –2 ,
2006 .
4.New approaches to cancer drug
development and clinical trials: questions and answers. Website of
the National Cancer Institute Available at http://www.cancer.gov/newscenter/pressreleases/PhaseZeroNExTQandA/print?page=&keyword=.
Accessed 18 June, 2008.
5.
Hill
T.P.
: Phase 0 trials: are
they ethically challenged?
Clin Cancer Res,
13 : 783 –784 ,
2007 .
6.
Marchetti
S.
,
Schellens
J.H.
: The impact of FDA and
EMEA guidelines on drug development in relation to phase 0
trials.
Br J Cancer , 97 :
577 –581 , 2007 .